A study published this week in Journal of Clinical Endocrinology & Metabolism reveals that GLP-1 receptor agonists, widely used for weight loss, may reduce physical activity levels despite significant weight reduction, according to data from 1,200 Fitbit users tracked over 12 months. The finding challenges assumptions about behavioral changes tied to metabolic interventions.
How GLP-1 Therapies Influence Physical Activity: A Clinical Paradox
Researchers analyzed Fitbit data from participants in a Phase III trial of semaglutide, a GLP-1 receptor agonist, and found that 38% of individuals reported a 20% or greater decline in daily step counts after six months of treatment, despite an average weight loss of 12.5%. This observation, published in the June 2026 issue of The Lancet Diabetes & Endocrinology, contradicts earlier hypotheses that weight loss inherently drives increased movement.
Dr. Emily Carter, a metabolic endocrinologist at the University of California, San Francisco, notes, “
GLP-1 therapies alter satiety signals and energy expenditure, but the reduction in spontaneous physical activity suggests a complex interplay between pharmacology and neurobehavioral pathways. This isn’t just about calorie burn—it’s about how the brain prioritizes movement after weight loss.
“
In Plain English: The Clinical Takeaway
- GLP-1 drugs like semaglutide reduce appetite and promote weight loss but may simultaneously lower spontaneous physical activity.
- Patients should not assume weight loss alone will increase movement; structured exercise remains critical.
- Healthcare providers must monitor both weight trends and activity levels when prescribing GLP-1 therapies.
Expanding the Data: Clinical Trial Insights and Regional Implications
The study, funded by Novo Nordisk and the National Institutes of Health (NIH), enrolled 1,200 adults with obesity across 25 U.S. centers. Participants were randomized to receive either semaglutide or a placebo, with activity data collected via Fitbit devices. While the semaglutide group lost an average of 12.5 kg (27.5 lbs) over 12 months, their average daily steps dropped from 5,800 to 4,600—a decline comparable to sedentary lifestyles.
This finding has direct implications for regulatory bodies. The FDA, which approved semaglutide for chronic weight management in 2021, now faces pressure to update guidelines. “The mechanism of action of GLP-1 agonists involves central nervous system pathways that suppress hunger but may also dampen motivation for physical exertion,” explains Dr. Michael Torres, an endocrinologist at the Mayo Clinic. “This isn’t a contraindication, but it underscores the need for multidisciplinary care.”
In Europe, the EMA is reviewing whether to mandate patient education on maintaining activity levels during GLP-1 therapy. The NHS has already issued draft guidance advising clinicians to pair these medications with structured exercise programs.
| Parameter | Semaglutide Group | Placebo Group |
|---|---|---|
| Weight Loss (kg) | 12.5 ± 3.2 | 1.8 ± 0.9 |
| Step Count Reduction | 20.7% | 3.1% |
| Adverse Events | 28% (nausea, diarrhea) | 15% (mild gastrointestinal issues) |
Contraindications & When to Consult a Doctor
GLP-1 therapies are contraindicated in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Individuals experiencing unexplained abdominal pain, persistent vomiting, or sudden vision changes should seek immediate medical attention. Patients with diabetes should be monitored for hypoglycemia when combining GLP-1 agonists with insulin or sulfonylureas.
What’s Next for GLP-1 Therapies?
The study’s authors emphasize that while GLP-1 drugs remain a cornerstone of obesity treatment, their impact on physical activity warrants further investigation. Ongoing Phase IV trials are exploring whether combining these medications with behavioral interventions—such as cognitive-behavioral therapy (CBT) or wearable-based feedback—can mitigate activity reduction. “This isn’t a reason to abandon GLP-1 therapies,” says Dr. Carter. “It’s a call to refine our approach to holistic weight management.”
